FDA weighs approval of a lucrative Alzheimer’s drug but benefits are iffy
06/04/2021

FDA weighs approval of a lucrative Alzheimer’s drug but benefits are iffy

The Food and Drug Administration's decision next week whether to approve the first treatment for...
read more